RxDoctor Payments Data

Isabel Bueno, MD

Internal Medicine · Jupiter, FLNPI 1194085415

Payments from drug & device makers

$7,560in general payments, 2019–2025

Across 339 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Bayer$2K
  • AstraZeneca$816
  • AbbVie$424
  • Lilly USA, LLC$406
  • Abbott$324
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$7119%
  • Food & beverage$6,75089%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,560 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$33,347
Medicare patients
222
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$73,849
JardianceEmpagliflozin50$72,709
PamelorNortriptyline Hcl15$42,726
OzempicSemaglutide28$35,389
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,734
XareltoRivaroxaban17$14,569
FarxigaDapagliflozin Propanediol11$12,368
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$10,182
Rosuvastatin Calcium357$4,652
Atorvastatin Calcium218$2,502
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,422
Metoprolol Succinate128$1,887
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$1,774
Sertraline Hcl41$1,729
SynthroidLevothyroxine Sodium13$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$111$82,89168 claims
PfizerEliquis$287$73,84961 claims
Novo NordiskOzempic$1,863$35,38928 claims
AstraZenecaBreztri Aerosphere, Farxiga$816$29,10230 claims
Johnson & JohnsonXarelto$17$14,56917 claims
AbbVieSynthroid$424$1,58213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →